Cubist Systematic Strategies, LLC Tcr2 Therapeutics Inc. Transaction History

Cubist Systematic Strategies, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $1,052 - $2,122	-566 Reduced 1.47%	38,005 $68,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $54,733 - $76,263	-25,940 Reduced 40.21%	38,571 $112,000
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $82,305 - $161,524	-34,294 Reduced 34.71%	64,511 $178,000
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $146,917 - $267,530	32,078 Added 48.07%	98,805 $460,000
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $297,915 - $647,718	35,298 Added 112.31%	66,727 $568,000
Q2 2021 Aug 16, 2021	BUY	$16.41 - $24.71 $13,702 - $20,632	835 Added 2.73%	31,429 $516,000
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $465,825 - $778,737	22,857 Added 295.42%	30,594 $676,000
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $147,003 - $252,458	7,737 New	7,737 $239,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.